Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Sep 3;15(9):e0238681.
doi: 10.1371/journal.pone.0238681. eCollection 2020.

Observational study of azithromycin in hospitalized patients with COVID-19

Alejandro Rodríguez-Molinero  1 , Carlos Pérez-López  2 , César Gálvez-Barrón  1 , Antonio Miñarro  3 , Oscar Macho  1 , Gabriela F López  1 , Maria Teresa Robles  1 , María Dolores Dapena  1 , Sergi Martínez  1 , Ezequiel Rodríguez  1 , Isabel Collado  1 ; COVID-19 research group of CSAPG
Affiliations
Observational Study

Observational study of azithromycin in hospitalized patients with COVID-19

Alejandro Rodríguez-Molinero et al. PLoS One. .

Abstract

Background: The rapid spread of the disease caused by the novel SARS-CoV-2 virus has led to the use of multiple therapeutic agents whose efficacy has not been previously demonstrated. The objective of this study was to analyze whether there is an association between the use of azithromycin and the evolution of the pulmonary disease or the time to discharge, in patients hospitalized with COVID-19.

Methods: This was an observational study on a cohort of 418 patients admitted to three regional hospitals in Catalonia, Spain. As primary outcomes, we studied the evolution of SAFI ratio (oxygen saturation/fraction of inspired oxygen) in the first 48 hours of treatment and the time to discharge. The results were compared between patients treated and untreated with the study drug through subcohort analyses matched for multiple clinical and prognostic factors, as well as through analysis of non-matched subcohorts, using Cox multivariate models adjusted for prognostic factors.

Results: There were 239 patients treated with azithromycin. Of these, 29 patients treated with azithromycin could be matched with an equivalent number of control patients. In the analysis of these matched subcohorts, SAFI at 48h had no significant changes associated to the use of azithromycin, though azithromycin treatment was associated with a longer time to discharge (10.0 days vs 6.7 days; log rank: p = 0.039). However, in the unmatched cohorts, the increased hospital stay associated to azithromycin use, was no significant after adjustment using Multivariate Cox regression models: hazard ratio 1.45 (IC95%: 0.88-2.41; p = 0.150). This study is limited by its small sample size and its observational nature; despite the strong pairing of the matched subcohorts and the adjustment of the Cox regression for multiple factors, the results may be affected by residual confusion.

Conclusions: We did not find a clinical benefit associated with the use of azithromycin, in terms of lung function 48 hours after treatment or length of hospital stay.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Process of selection of matched controls.
Fig 2
Fig 2. Flow diagram.
Fig 3
Fig 3. Kaplan-Meier comparison curves and log-rank test outcomes of the different subcohorts (unadjusted).
See this image and copyright information in PMC

References

    1. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020. March;55(3):105924 10.1016/j.ijantimicag.2020.105924 - DOI - PMC - PubMed
    1. WHO Director-General’s opening remarks at the media briefing on COVID-19–11 March 2020 [Internet]. [cited 2020 May 20]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-re...
    1. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, et al. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. Int J Environ Res Public Health. 2020. 14;17(8). - PMC - PubMed
    1. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC-C, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020. April 27; - PMC - PubMed
    1. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020. March 27; - PMC - PubMed

Publication types